^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
211At-OKT10-B10
i
Other names: 211At-OKT10-B10, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Astatine-211-OKT10-B10, At211-OKT10-B10, Astatine 211-labeled Anti-CD38 Monoclonal Antibody OKT10-B10
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Fred Hutchinson Cancer Center
Drug class:
CD38 inhibitor, Alpha radiation emitter
Related drugs:
9ms
Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma (clinicaltrials.gov)
P1, N=0, Withdrawn, Fred Hutchinson Cancer Center | N=30 --> 0 | Recruiting --> Withdrawn
Enrollment change • Trial withdrawal
|
CD34 (CD34 molecule)
|
melphalan • 211At-OKT10-B10
1year
Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma (clinicaltrials.gov)
P1, N=30, Recruiting, Fred Hutchinson Cancer Center | Withdrawn --> Recruiting | Trial completion date: Mar 2026 --> Sep 2027 | Trial primary completion date: Mar 2024 --> Oct 2025
Enrollment open • Trial completion date • Trial primary completion date
|
CD34 (CD34 molecule)
|
melphalan • 211At-OKT10-B10
1year
Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma (clinicaltrials.gov)
P1, N=0, Withdrawn, Fred Hutchinson Cancer Center | N=30 --> 0 | Recruiting --> Withdrawn
Enrollment change • Trial withdrawal
|
CD34 (CD34 molecule)
|
melphalan • 211At-OKT10-B10
over2years
Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma (clinicaltrials.gov)
P1, N=24, Recruiting, Fred Hutchinson Cancer Center | Not yet recruiting --> Recruiting
Enrollment open
|
CD34 (CD34 molecule)
|
melphalan • 211At-OKT10-B10
Share via
